Lipodystrophy severity does not contribute to HAART nonadherence.
Lipodystrophy severity among 77 people living with HIV/AIDS (PHA) with body fat redistribution was not related to antiretroviral adherence including doses missed during the previous month, categorical rating of maximal adherence, and the PMAQ7 adherence behavior scale. Two thirds of the sample reported submaximal adherence, 19% missing more than two doses, but adherence behavior ratings reflected good overall adherence. Overall symptom burden, convenience of regimen schedule and remembering to organize and take antiretroviral doses, but not regimen adaptation or treatment support, were associated with adherence. Remembering was most strongly related to adherence indicators, retaining statistical significance in adjusted multivariate regression analyses.
Collins
Evan J
EJ
Immunodeficiency Clinic, Toronto General Hospital, Toronto, Canada.
Burgoyne
Robert W
RW
Wagner
Cheryl A
CA
Abbey
Susan E
SE
Halman
Mark H
MH
Nur
Margaret L
ML
Walmsley
Sharon L
SL
D000368:Aged; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology*; D039682:HIV-Associated Lipodystrophy Syndrome / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D012944:Social Support; D016312:Treatment Refusal / Q000706:statistics & numerical data*